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Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is the most common neurologi‐
cal side effect of chemotherapy and is characterized by damage to the nervous system
that is a direct result of the medications associated with chemotherapy. Often, this damage
to the central nervous system pain pathways results in neuropathic pain described as
burning, paroxysmal, stabbing, or elective shock-like and accompanied by pins-and-
needles sensations and itching. The presence and severity of neuropathic pain is often
shown to be associated with impairments in walking, general activities, sleep, work, mood,
enjoyment of life, and relationships with others. Treatment of neuropathic pain due to
CIPN often requires a multidisciplinary approach due to the broad variety of symp‐
toms and their negative impact on quality of life. To provide treatment strategies that are
effective for patients, they should include a combination of pharmacological agents and
exercise rehabilitation. Exercise rehabilitation programs should be designed in order to
help patients familiarize themselves to changes in physical functioning. The goals of the
program should target three main areas: maximize functional capacities, prolong or
maintain independent function, and improve quality of life.
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1. Introduction
Treating cancer requires an understanding of cellular kinetics [1]. DNA mutations that occur
during DNA replication can aide in the development of cancer cells. Activation for DNA repair
in a normal cell cycle uses checkpoints to facilitate the repair; however, checkpoint integrity is
lost in tumor cells and DNA repair is bypassed [2]. The resulting mutations impact the regulatory
mechanisms the restrict cell proliferation in a normal cell [3].
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The use of chemotherapeutic agents works by disrupting the cell cycle to prevent cell
proliferation before it begins [4]. The negative of systemic chemotherapeutic agents is that
normal cells, as well as malignant cells, are disrupted. This leads to untoward effects and long-
term morbidities [4] that negatively impact functional ability and quality of life. Chemother‐
apy-induced peripheral neuropathy (CIPN) is the most common neurological side effect of
chemotherapy [5]. This condition is characterized by damage to the nervous system that is a
direct result of the medications associated with chemotherapy. Often, this damage to the
central nervous system pain pathways results in neuropathic pain [6], frequently described as
burning, paroxysmal, stabbing, or elective shock-like [7], accompanied by pins-and-needles
sensations and itching. The presence and severity of neuropathic pain is often shown to be
associated with impairments in walking, general activities, sleep, work, mood, enjoyment of
life, and relationships with others [2, 8].
Little is known about the mechanisms responsible for the development of CIPN [4]. The
peripheral toxicity involved with CIPN is specific to each chemotherapy drug class and
appears to be dose and duration dependent. However, it can evolve even after a single-drug
application [9]. The type and cause of neuropathy are dependent on the chemotherapy agent
administered, with vincristine, paclitaxel, and cisplatin being the most neurotoxic [10].
Currently, prophylactic and symptomatic treatments have been ineffective because the
neurobiology underpinning CIPN is not fully understood [11]. Thus, the purpose of this
chapter was to outline the differences in treatment options available to patients with CIPN and
analyze the benefits of exercise in the management of symptoms related to this disorder.
2. Etiology of CIPN
In healthy individuals, peripheral and central nervous system pain pathways function in a
protective and adaptive manner [12]. The transduction, conduction, and transmission of
nociceptor activity involve these pathways when carrying out activity within the cell. Whether
induced by cancer or its treatments, damage to these pathways can result in neuropathic
pain [13]. Discontinuation of treatment can result in the development of acute and chronic
neurotoxic effects, and these effects can be seen immediately or within weeks or months after
discontinuation. Symptoms seen immediately following the first course of treatment can often
be contributed to vincristine and oxaliplatin-based regimens. Though both regimens typical‐
ly produce symptoms immediately following treatment, these symptoms vary between
treatments. Vincristine use typically involves the cranial nerve and can lead to symptoms such
as seizures, quadriparesis, and numbness. In contrast, oxaliplatin use often produces acute
sensory symptoms seen in the mouth or throat that can be intensified by exposure to cold [14].
Regimens that do not present symptoms for up to several weeks after the final treatment may
induce a length-dependent neuropathy on small fibers [15].
Incidence of CIPN is estimated to range anywhere from 10 to 100%, depending on the
antineoplastic agent, dose, and other factors as presented by the patient [16]. Patients previ‐
ously affected by diabetes, alcoholism, or inherited neuropathies may be at an increased risk
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for CIPN [1, 16]. Clinical diagnosis of CIPN is complex, as there is often more than one
contributing mechanism [17]. Therefore, testing is multi-faceted and includes neurological
examination, quantitative sensory testing, nerve conduction studies, and toxicity grading.
Positive symptoms include hypersensitivity to innoculous and noxious stimuli, such as gentle
and/or blunt pressure and pinprick [18, 19].
3. Impact on quality of life
Neuropathic pain negatively affects health-related quality of life. Specifically, decrements to
physical [20–22], emotional [20, 21, 23], and social functioning [21, 22, 24] are noted in patients
with CIPN. In addition, sleep [20, 21, 24, 25] and global quality of life [3, 26] are disturbed. The
presence and severity of pain was reported to cause depression and anxiety in patients [20, 21,
23].
4. Treatment strategies
Treatment of neuropathic pain due to CIPN often requires a multidisciplinary approach due
to the broad variety of symptoms and their negative impact on quality of life. To provide
treatment strategies that are effective for patients, they should include a combination of
pharmacological agents and exercise rehabilitation.
4.1. Pharmacological agents
There has been much effort put into exploring pharmacological therapies to effectively reduce
CIPN. To date, research has shown that some of these therapies provide modest improve‐
ments in neurological function. Unfortunately, in some cases, these agents have been shown
to have additional negative side effects for cancer patients. The following text provides a
discussion of some of these agents, their mechanism of action, and possible side effects.
Alpha-lipoic acid is a cyclic disulfide broad-spectrum antioxidant [27] that has been recently
used in research for treatment of CIPN. It has been shown to be effective in animal subjects of
CIPN treated with oxaliplatin, cisplatin, and vincristine. Alpha-lipoic acid has the ability to
enter all parts of a nerve because it displays the unique capability of functioning in both water
and fat. They utilize this ability and other mechanisms by involving the regulation of acetyl-
CoA, acetylation of tubulin, and increasing NGF-induced histone acetylation [28]. Alpha-lipoic
acid also increases the formation of glutathione and is involved in the recycling of antioxi‐
dants such as glutathione, vitamin C, and vitamin E [29]. A few possible side effects of the
treatment includes headache, tingling, pins-and-needles sensation, rash, and muscle cramps.
Another possible treatment for CIPN is carbamazepine; a sodium-channel inhibitor prescri‐
bed in the treatment of epilepsy. Sodium channel dysfunction is linked to oxaliplatin-in‐
duced peripheral neuropathy [30] and carbamazepine has been reported to be an effective
treatment against certain forms of pain associated with oxaliplatin. The reported areas of
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effectiveness with carbamazepine have been against the lancing and shooting pain compo‐
nents with less effectiveness seen in burning pain sensations [31]. Side effects of using
carbamazepine include dizziness, drowsiness, and headache, as well as cardiac conduction
defects, abnormalities in antidiuretic hormone secretion, loss of balance, and diplopia [9].
Another solution used in the treatment of epilepsy that has been recently acknowledged for
its role in treating neuropathic pain is gabapentin. Gabapentin has been found to be effective
in painful diabetic neuropathy [32] by binding with subunits of the calcium channel [33]. It
was originally developed as a γ-aminobutyric acid (GABA) analogue and has been associat‐
ed with symptoms such as fatigue, blurred or double vision, muscle pain, swelling in
extremities, tremor, and drowsiness [34].
Previously, it has been reported that individuals with cancer more often than not have shown
reduced levels of glutamine. Glutamine is an amino acid that functions as the primary energy
source for rapidly proliferating cells. It also plays a significant role in the upregulation of nerve
growth factor, mRNA [35]. Additionally, studies involving human subjects report reduced
levels of nerve growth factor during therapy [36]. Together, these findings provide support
the use of glutamine as a neuroprotective agent in individuals with cancer.
Glutathione is an antioxidant and antiviral tripeptide. It has been reported that concurrent
administration of glutathione and cisplatin results in a reduction of CIPN. This is thought to
be due to a reduction in platinum deposits, as glutathione has a high affinity for heavy
metals [37, 38]. However, increased levels of glutathione have been linked to chemotherapy
resistance in bone marrow, breast, colon, larynx, and lung cancers [39].
Lamotrigine is a neuroprotective agent that stabilizes sodium channels. In vitro studies suggest
that lamotrigine modulates the release of glutamate. Studies examining its efficacy have
reported positive effects on diabetic neuropathy [40] and neuropathic pain in the elderly [41].
Adverse effects include loss of balance, dizziness, fatigue, memory and cognitive problems,
and drowsiness [40].
Phenytoin is an anticonvulsant drug that works as a sodium channel stabilizer, which works
to reduce neuronal excitability. Phenytoin has recently been seen to be effective at decreas‐
ing visual analogue scale pain scores [42]; however, excessive use of the drug has been
associated with neurological problems such as horizontal gaze. Other associated problems
include loss of balance, drowsiness, dizziness, and inhibited insulin release.
Valproic acid has been used quite extensively in the management of neuropathic pain [43];
however, there is little evidence to support its clinical use currently. It is believed to increase
levels of GABA in the brain, yet its mechanism of action is unknown. Side effects reported with
use of the drug include a decrease in blood clotting mechanisms, which may lead to exces‐
sive bleeding. Valproic acid has also been associated with side effects such as drowsiness,
dizziness, nausea, vomiting, and tremors [43].
Venlafaxine is a drug that has traditionally been used as an antidepressant, but is currently
being looked at for its beneficial effects in cancer patients. Venlafaxine works in the selective
reuptake of serotonin and norepinephrine and has been recently found to lessen the hyperex‐
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citability of peripheral nerves [44]. However, reported side effects with venlafaxine can include
headaches, anxiety, drowsiness, and increased blood pressure.
Vitamins have also been studies as a possible means of controlling symptoms of neuropathy.
Vitamin E is a fat-soluble antioxidant that prevents the peroxidation of polyunsaturated fatty
acids. Typically in patients with peripheral neuropathy, there is usually an accompanied
deficiency of vitamin E [45] and a greater chance of developing fat-malabsorption disorders.
Vitamin E supplementation during treatment with paclitaxel or cisplatin [46, 47] has demon‐
strated evidence of neuroprotection in clinical trials. These same trials have indicated that
Vitamin E supplementation may reduce mortality rates associated with certain forms of
cancer [48].
Other prophylactic agents that have been identified as potential neuroprotective agents in
CIPN include amifostine, corticosteroids, diethyldihiocarbamate, electrolyte infusions,
recombinant human leukemia inhibitory factor, nimodipine, and ORG-2766. These agents
have only been tested in animal populations; however, human studies have shown little or no
evidence of neuroprotection [49–55].
4.2. Exercise rehabilitation
Most preventative and treatments option thus far have come accompanied with a variety of
side effects. Due to this, options other than the use of pharmacological interventions that target
CIPN should be considered. Exercise rehabilitation is a potential avenue for preventative
measures as well as alleviating CIPN symptoms in cancer patients. Many previous research
trials have shown beneficial effects of exercise in offsetting countless cancer treatment-related
toxicities as well as enhancing the quality of life of the patients. However, clinical trials
examining the role of exercise in preserving neurological function following chemotherapy
are limited. One recent investigation on the current exercise behaviors of breast cancer patients
diagnosed with CIPN patients reported that those individuals who met the amount of
recommended physical activity levels reported a significantly higher quality of life and
experienced significantly less pain than their sedentary counterparts [56]. A follow-up
investigation examined the effect of 12 weeks of supervised exercise training on symptoms of
CIPN and found that exercise training positively impacted neurological function. Specifically,
unpleasant skin sensations and sensitivity related to neuropathic pain were attenuated
following chronic exercise training [57].
While the mechanisms underlying the role of exercise in neuroprotection are unclear, several
theories have been circulated. With neuropathy, muscle mass atrophies cause significant
decreases in muscular strength [24]. This decline in strength appears to be slow and progres‐
sive. It also appears to affect distal muscle groups more so than proximal muscles. Research‐
ers have indicated that this muscle weakness translates into impaired motor performance skills
and a reduced exercise capacity [29]. However, several studies have reported improvements
in muscular strength following moderate resistance exercise programs in patients with
hereditary motor and sensory neuropathies [20, 21], as well as diabetic neuropathies, and those
associated with fibromyalgia and chronic fatigue [3, 26–28, 39, 40]. In light of these findings,
many researchers recommend that exercise training serve as an important component in the
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comprehensive treatment plan for patients with peripheral neuropathy [3, 23, 27]. Moderate
to intense strength training and aerobic exercise appears to be well tolerated by these pa‐
tients [23] and is associated with improvements in motor function and nerve conduction
velocity [26, 28], as well as improved muscle reinnervation and increased axon regeneration
[22]. In addition, one investigation reported that low intensity treadmill exercise promoted
Schwann cell proliferation in the injured peripheral nerve [25]. In light of these findings, it is
feasible to assume that an individual who has experienced a reduction in muscular strength
and functional ability due to CIPN may experience similar improvements following an exercise
program.
Those affected by CIPN typically experience large amounts of pain associated with peripher‐
al neuropathy and can be severe enough that it interferes with an individual’s quality of life
[13]. This type of pain has long been recognized as one of the more difficult types of pain to
treat; however, exercise rehabilitation may be able to reduce the amount of pain accompany‐
ing peripheral neuropathy. In healthy individuals, studies have shown that acute exercise can
temporarily decrease pain perception; a condition known as exercise-induced hypoalgesia
(EIH). Specifically, there have been reported increases in pain thresholds and pain tolerance
levels both during and after exercise. Even further, there appears to be a decrease in intensi‐
ty ratings of pain following exercise. To date, research in these areas has yet to determine the
optimal intensity of aerobic exercise needed to produce a hypoalgesic effect [58–63]. Typically,
exercising at intensities between 60 and 75% of maximum heart rate has been found to produce
EIH [58, 59]. Thus far, it has been reported that women tended to experience hypoalgesia
following aerobic exercise at 85% HRmax [60]. In most research that has been performed, subject
has self-selected their aerobic exercise intensities in which they reported EIH following the
exercise bout [61, 62]. EIH has also been observed following resistance exercise training, though
reports are limited in this area. In a study conducted by Koltyn and Arbogast [63], it was shown
that following 45 min of resistance exercise at 75% of the subject’s 1-RM, increases in pain
thresholds were observed.
Exercise rehabilitation programs should be designed in order to help patients familiarize
themselves to changes in physical functioning. Further, goals of the program should target
three main areas: maximize functional capacities, prolong or maintain independent function,
and improve quality of life. For example, studies performed using populations with heredi‐
tary motor and sensory neuropathy have shown that a minimum of 12 weeks of low to
moderate resistance training (approximately 30% overload) resulted in strength gains [64–66]
that improved function ability [67]. An important area of concern for resistance training is
watching for signs that indicate the muscles are being over-worked or exhausted. Symptoms
of muscle exhaustion include, but are not limited to, muscle weakness within a half hour of
completion of the exercise and excessive muscle soreness between 24 and 48 h after exercise
[76, 77]. Training programs should also target aerobic exercise due to its associated benefits
with cardiovascular performance and pain tolerance as well as decreased fatigue and
depression scores. Currently, research suggests that endurance-based programs should be low
impact or utilize approximately 50% of the patient’s heart rate reserve [68, 69]. Studies in this
area also suggest including a proper warm up and cool down component.
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5. Summary
In closing, CIPN is a dose-limiting effect of cancer therapy that has negative implications on
a patient’s quality of life. While much effort has been made to explore pharmacological
therapies aimed at cancer patients. However, exercise rehabilitation is one lifestyle
modification that positively impacts the lives of patients with CIPN.
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